XML 47 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCK-BASED COMPENSATION (Tables)
9 Months Ended
Sep. 30, 2022
Summary of Stock option and restricted stock activity

A summary of stock option and restricted stock activity under the 2022 Plan and Inducement Grants during the nine months ended September 30, 2022 and 2021 is presented below:

​

​

​

​

​

​

​

​

​

(in thousands)

​

Options

​

Inducement Grants

​

RSAs

​

Outstanding at December 31, 2020

 

756

​

180

​

352

​

Granted

 

97

​

61

​

463

​

Options Exercised/RSAs Vested

 

(5)

​

—

​

(126)

 (1)

Forfeited

 

(74)

​

—

​

(61)

​

Expired

 

—

​

—

​

—

​

Outstanding at September 30, 2021

 

774

​

241

​

628

​

​

​

​

​

​

​

​

​

Outstanding at December 31, 2021

 

747

​

241

​

707

​

Granted

 

36

​

—

​

723

​

Options Exercised/RSAs Vested

 

(16)

​

—

​

(234)

 (2)

Forfeited

 

(58)

​

—

​

(46)

​

Expired

 

—

​

—

​

—

​

Outstanding at September 30, 2022

 

709

​

241

​

1,150

​

(1)Includes 28 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $0.9 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets.
(2)Includes 63 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $1.9 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets.
2016 Employee Stock Purchase Plan  
Summary of allocated expense

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

(in thousands)

​

Three Months Ended September 30, 

​

Nine Months Ended September 30, 

​

​

    

2022

    

2021

    

2022

    

2021

    

Cost of sales

​

$

11

​

$

3

​

$

40

​

$

11

​

Research and development

​

 

10

​

 

5

​

 

31

​

 

16

​

Selling, general, and administrative

​

 

82

​

 

20

​

 

142

​

 

66

​

​

​

$

103

​

$

28

​

$

213

​

$

93

​

2022 Plan  
Summary of allocated expense

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

(in thousands)

​

Three Months Ended September 30, 

​

Nine Months Ended September 30, 

​

​

    

2022

    

2021

    

2022

    

2021

    

Cost of sales

​

$

134

​

$

2

​

$

393

​

$

4

​

Research and development

​

 

186

​

 

144

​

 

531

​

 

407

​

Selling, general, and administrative

​

 

3,447

​

 

2,634

​

 

9,725

​

 

7,017

​

​

​

$

3,767

​

$

2,780

​

$

10,649

​

$

7,428

​